Dear Doctor - Participate in the Survey on hepatitis of unknown etiology " A recent survey of hepatitis cases of unknown etiology in children found that the vast majority of cases were in infants under the age of 6 months. The most common symptoms reported were fever, diarrhea, and vomiting. However, a small number of children also had jaundice and liver enzymes that were elevated. The most common tests used to diagnose hepatitis are the alanine aminotransferase (ALT) test and the aspartate aminotransferase (AST) test. These tests can be used to identify liver damage and determine the cause of the hepatitis. In some cases, additional testing, such as a viral load test or a liver biopsy, may be needed to confirm the diagnosis. Treatment for hepatitis usually involves supportive care, such as rest and fluids, and may also include medications to reduce liver inflammation or suppress the immune system. Participate in Surveys "
1.
Examines Office-Based Transperineal Prostate Biopsies Methodology.
2.
Patients value communication skills from cancer surgeons across six key areas, according to research
3.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
4.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
5.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
1.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
2.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
3.
Iron Deficiency Anemia: Challenges in Diagnosis and Treatment
4.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
5.
The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation